Epigenomics AG / Veröffentlichung der Gesamtzahl der Stimmrechte 28.11.2014 16:30 Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG, übermittelt durch DGAP – ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ————————————————————————— Hiermit teilt die Epigenomics AG mit, dass die Gesamtzahl der Stimmrechte am Ende des Monats November […]
Author: mark
28. November 2014
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung
Read more
11. November 2014
Epigenomics AG: Epigenomics AG Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): 9-month figures 11.11.2014 / 08:30 Epigenomics AG Announces 2014 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights Berlin (Germany) and Germantown, MD (U.S.A.), November 11, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results […]
03. November 2014
Epigenomics AG: Epigenomics’ strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States
Epigenomics AG / Key word(s): Alliance 03.11.2014 / 10:34 Epigenomics’ strategic commercialization partner Polymedco reiterates its commitment to support Epi proColon(R) in the United States Berlin (Germany) and Germantown, MD (USA), November 03, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that Polymedco, Inc., a […]
27. October 2014
Epigenomics AG: Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening
Epigenomics AG / Key word(s): Scientific publication 27.10.2014 / 08:30 Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening Berlin (Germany) and Germantown, MD (U.S.A), October 27, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced […]
16. October 2014
Epigenomics AG: Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain
Epigenomics AG / Key word(s): Capital Increase 16.10.2014 / 09:30 Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), October 16, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company […]
01. October 2014
Epigenomics AG: Epigenomics Provides Corporate Update
Epigenomics AG / Key word(s): Miscellaneous 01.10.2014 / 14:00 Epigenomics Provides Corporate Update Berlin (Germany) and Germantown, MD (U.S.A.), October 1, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today provides a corporate update on major developments. Epigenomics, in consultations with the U.S. Food and Drug Administration […]